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Background: Genome-wide association studies (GWAS) have identified many common single nucleotide
polymorphisms (SNPs) that associate with clinical phenotypes, but these SNPs usually explain just a small part of
the heritability and have relatively modest effect sizes. In contrast, SNPs that associate with metabolite levels
generally explain a higher percentage of the genetic variation and demonstrate larger effect sizes. Still, the
discovery of SNPs associated with metabolite levels is challenging since testing all metabolites measured in typical
metabolomics studies with all SNPs comes with a severe multiple testing penalty. We have developed an
automated workflow approach that utilizes prior knowledge of biochemical pathways present in databases like
KEGG and BioCyc to generate a smaller SNP set relevant to the metabolite. This paper explores the opportunities
and challenges in the analysis of GWAS of metabolomic phenotypes and provides novel insights into the genetic
basis of metabolic variation through the re-analysis of published GWAS datasets.
Results: Re-analysis of the published GWAS dataset from Illig et al. (Nature Genetics, 2010) using a pathway-based
workflow (http://www.myexperiment.org/packs/319.html), confirmed previously identified hits and identified a new
locus of human metabolic individuality, associating Aldehyde dehydrogenase family1 L1 (ALDH1L1) with serine/
glycine ratios in blood. Replication in an independent GWAS dataset of phospholipids (Demirkan et al., PLoS Genetics,
2012) identified two novel loci supported by additional literature evidence: GPAM (Glycerol-3 phosphate acyltransferase)
and CBS (Cystathionine beta-synthase). In addition, the workflow approach provided novel insight into the affected
pathways and relevance of some of these gene-metabolite pairs in disease development and progression.
Conclusions: We demonstrate the utility of automated exploitation of background knowledge present in pathway
databases for the analysis of GWAS datasets of metabolomic phenotypes. We report novel loci and potential
biochemical mechanisms that contribute to our understanding of the genetic basis of metabolic variation and its
relationship to disease development and progression.
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GWAS have resulted in the identification of novel gen-
etic loci associated with a variety of diseases and clinical
phenotypes. However, a disease or clinical phenotype is
the end point of the behaviour of numerous genes and
pathways in addition to environmental influences. This
at least partly explains the general observation that the
effect size of genetic association with clinical phenotypes
is rather small. Spurred by recent technological develop-
ments in the field of metabolomics, interest in genome
wide association studies with metabolite levels in blood
[1-4] is gathering momentum. Metabolites are inter-
mediate phenotypes, entities that lie between genes and
clinical end points [5,6]. Due to their proximity to an en-
zyme/gene, metabolites may offer greater effect sizes for
GWAS than clinical phenotypes [7]. Moreover, the path-
ways in which the metabolite plays a role may provide
insight into the underlying biological mechanism re-
sponsible for the development of the associated disease.
Typically, in metabolomics GWAS, hundreds of me-
tabolites are tested for genetic association. However, as-
sociation of all SNPs with all measured metabolites
comes with considerable multiple testing problems. Re-
cent publications have also shown that testing ratios of
metabolites for genetic association results in much larger
effect sizes; however this further exacerbates the mul-
tiple testing problem which precludes genuine SNP-
metabolite pairs from reaching genome-wide signifi-
cance. Several approaches like gene based tests [8,9] and
pathway analysis [10] have been proposed to overcome
this limitation of inadequate statistical power in GWAS.
All these approaches have been suggested in the context
of GWAS with clinical phenotypes but genetic associ-
ation with metabolites presents its own set of unique op-
portunities and challenges. Herewith, we explore the
utility of background knowledge present in metabolic
pathway databases to increase the power in identification
of metabolite Quantitative Trait Loci (mQTL).
Our approach involves selective testing of SNPs near
genes in pathways supposedly relevant to the metabolite
levels, as a way to reduce the multiple testing burden in
GWAS. Background knowledge pertaining to a metabol-
ite is retrieved through systematic interrogation of meta-
bolic pathway databases which describe biochemical
pathways, reactions, and enzymes relevant to human
metabolism. Several pathway databases have been cre-
ated by groups around the world, while the intent of
these efforts remains the elucidation of biological mech-
anism, the databases however, differ quite significantly in
their content, size, user accessibility, download formats
and most importantly availability and type of web ser-
vices for machine-enabled interrogation of the database
[11]. In this publication, as a proof of principle, we have
chosen to focus on two important metabolic pathwaydatabases, KEGG [12] and BioCyc [13]. KEGG is an inte-
grated database resource of seventeen databases which
provide system, genomic and chemical information. The
pathway database consists of both metabolic and non-
metabolic pathways and is constructed by a team of cu-
rators based on information available in the literature.
BioCyc is a collection of pathway/genome databases that
describe the genome and metabolic pathways of several
organisms. The database that describes human genomes
and pathways, HumanCyc was interrogated in this study.
In our approach, for every metabolite under consider-
ation, genes acting in the vicinity of the metabolite are
determined using knowledge present in databases men-
tioned above. We thus generate an integrated set of
genes that represent entities with influence over the me-
tabolite. A workflow management system called Taverna
[14] was used to generate these gene sets and the SNPs
associated with these genes. The workflows that were
designed for this purpose have been submitted to a
workflow repository at http://www.myexperiment.org/
packs/319.html [15].
A previously published metabolomics dataset by Illig
et al. 2010 [2] was analyzed to evaluate the sensitivity of
the method in picking true positives and to identify
novel SNP-metabolite pairs that had hitherto been ob-
scured in the GWA list given the stringent threshold for
significance. In addition to validating a novel bioinfor-
matics workflow analysis tool, we identified a new locus
of human metabolic individuality, Aldehyde dehydrogen-
ase family1 L1 (ALDH1L1). This locus was found associ-
ated with serine/glycine ratios, a metabolic trait that
functionally matches the gene function.
Candidate genes identified through the analysis of Illig
et al. dataset were taken up for replication in a separate
study published by Demirkan et al. [4]. We report
GPAM (Glycerol-3 phosphate acyltransferase) and CBS
(Cystathionine beta-synthase) as novel loci associated
with phosphatidylcholine moieties.
Results
Our approach can be divided into three stages: (i) Gener-
ate a non-redundant gene set for every metabolite consid-
ered using knowledge in pathway databases like KEGG
and BioCyc applying interrogation schemes as shown in
Figure 1 and outlined below. (ii) For every gene in the set,
generate the set of SNPs within the gene and 50 kb flank-
ing sequences, and create a SNP set for each metabolite
(iii) Match SNPs generated for a metabolite with the
GWAS for the same metabolite and store the matches
with the p-values reported for the association (Figure 2).
Analysis strategy of databases and Interrogation schemes
To retrieve a prioritized list of candidate genes associ-
ated with metabolite levels, gene sets were generated for
B. Reaction Scheme
Metabolite
Get reactions that the 
metabolite participates in
Get compounds that 
participate in these reactions
Get reactions that these 
compounds participate in
Get enzymes that drive 
these reactions
Get genes corresponding
to these enzymes
FILTER COMPOUNDS
GENE SET
A. Pathway Scheme
Metabolite
Get Pathways
Get all genes in 
these pathways
GENE SET
FILTER FOR METABOLIC 
PATHWAYS (KEGG)
Figure 1 The database interrogation schemes. The two
interrogation schemes: pathway scheme (A) and reaction scheme
(B) are shown. The blue color indicates the intermediate steps to
filter out certain pathways/compounds from the two schemes to
avoid non-specific connections.
Generate non-redundant
Gene Set for metabolite X 
Match SNPs present in both sets. Report
matched SNPs and association p-values
GWAS data for metabolite X
(Example: Illig et al 2010, data) 
Generate Gene Set for metabolite X using schemes 
shown in Fig1 applied to both KEGGand BioCyc 
databases
Generate SNP Set for
metabolite X
Figure 2 Strategy to find biologically relevant SNP-metabolite
pairs in published GWAS datasets. Background knowledge
pertaining to a metabolite is collected from the pathway databases
KEGG and BioCyc in an automated fashion to generate a gene/SNP
set relevant to the synthesis and degradation of the metabolite.
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action scheme [Figure 1A and 1B] for the KEGG and
BioCyc databases (see Method). The pathway scheme
generates a list of genes that participate in pathways
relevant to the synthesis or degradation of the metabol-
ite. In the reaction scheme, the metabolite is used as a
seed node and shells of reactions around the metabolite
are explored. The list of genes that catalyse the reactions
are retrieved and form the gene set for the given metab-
olite. For every gene set, a corresponding SNP set is gen-
erated by retrieving SNPs within the flanking 50 kb of
every gene. In the final step, the SNP set for a metabolite
is matched with the GWAS dataset for the same metab-
olite. At this stage, the sensitivity of the method is evalu-
ated and potential novel discoveries are explored.
Results for each of three classes of metabolites (14
amino acids, 1 carnitine and 2 lipids) are shown in
Table 1. For example, for glycine, interrogation of the
KEGG database identified 173 and 432 genes using the
pathway and reaction schemes respectively, whereas the
corresponding numbers of genes were 90 and 192 for
the BioCyc database. The union of all the four interroga-
tion schemes results in a gene set consisting of 523
genes relevant to glycine metabolism (Table 1). For all
the three classes of metabolites, 1246 unique genes were
found, 640 are common to KEGG and BioCyc, the num-
ber of genes unique to each of the two databases are 379
and 227 respectively (Figure 3).
Statistical threshold
The number of unique SNPs generated for each of the
metabolites is shown in Table 1. For aggregated metabo-
lites like phosphatidylcholines, sphingomyelins and car-
nitines the size of the unique SNP set is multiplied by
the number of metabolites that fall within each class to
yield the total number of tests. For example, the size of
the unique SNP set for carnitine is 11,239; this is multi-
plied by the number of carnitines which is 41, to yield a
total number of 460,799 tests for these compounds, as
shown in the last column of Table 1. The sum of all
SNPs derived from our set of metabolites is 3,835,543.
The multiple testing threshold for metabolite concentra-
tions using a Bonferroni correction at a nominal p-value
of 0.05 is 1.3E-08 (0.05/3,835,543). In contrast, the p-
value threshold for significant association of SNPs with
the same metabolite concentrations in the Illig et al.
study would be 5.96E-10 (0.05/162*517,840). This repre-
sents a reduction of the multiple testing burden by about
two orders of magnitude, regardless of the dependency
between the SNPs or metabolites.
It has been demonstrated that GWAS of metabolite
ratios offer robust statistical associations and point to
biological mechanisms related to the interconversion of
metabolite pairs. To investigate the association of SNPs
Table 1 Gene and SNP sets generated by the database: interrogation schemes for each of the metabolites
Metabolite BioCyc
Pathway
BioCyc
Reaction
KEGG
Pathway
KEGG
Reaction
Size of unique
gene set1
Size of unique
SNP set2
Number
of tests3
Arginine 20 104 57 179 257 10788 10788
Glutamine 51 132 100 282 388 15591 15591
Glycine 90 192 173 432 523 20767 20767
Histidine 8 9 45 155 181 7126 7126
Leucine 8 0 44 83 117 5037 5037
Methionine 27 104 35 243 284 11532 11532
Ornithine 16 150 103 159 247 10089 10089
Phenylalanine 6 113 25 163 196 8419 8419
Proline 10 12 57 83 119 5075 5075
Serine 37 135 152 219 360 14996 14996
Threonine 1 11 39 49 75 2633 2633
Tryptophan 15 19 78 221 261 10419 10419
Tyrosine 14 106 61 158 219 9365 9365
Valine 15 93 80 137 211 9365 9365
Carnitine 32 206 81 94 263 11239 460799
Phosphatidylcholine 188 361 312 343 640 31676 2914192
Sphingomyelin 160 331 189 241 460 21290 319350
Sum 698 2078 1631 3241 4801 205407 3835543
Unique set 399 806 703 768 1246 55952 55952
The number of genes for each metabolite and the corresponding database:interrogation scheme is shown. 1 The size of the union of the gene set obtained from
all the four database:interrogation schemes. 2 The size of the corresponding SNP set. 3 The number of tests is the same as the size of the SNP set for the amino
acids whereas for aggregated entities like the lipids and carnitine the SNP set is multiplied by the number of compounds present in that class.
Figure 3 Gene set overlap for the KEGG and BioCyc databases.
The Venn diagram depicts the overlap between the non-redundant
gene set for KEGG and the BioCyc metabolic pathway database.
These genes correspond to the combined set from the pathway and
reaction interrogation schemes. The total number of unique genes
that our method yields is 1246.
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sets for all combinations of metabolites (Additional file
1: Table S3). In the case of aggregated metabolites like
the lipids and carnitines, the union of the SNP set is
multiplied by the number of compounds that fall within
each class. For example, the union of the SNP set for ar-
ginine and carnitine is 20,000, this is multiplied by 41 to
yield the total number of 820,000 tests for this group of
ratios. The number of tests for ratios of compounds
within classes such as phosphatidylcholines is equal to
the size of the unique SNP set multiplied by the number
of combinations, n*(n-1)/2, which in this case would be
92*91/2 = 4186. In choosing combinations of ratios, we
have assumed that the association p-value for a linear re-
gression model using a metabolite ratio of A/B is equiva-
lent to that computed using it’s reciprocal, B/A. The
evidence for lack of independence of a ratio and its recip-
rocal is provided by the Illig et al. study where a compari-
son of associations computed using untransformed and
log-scaled ratios did not detect significant differences. This
implies that we may consider the p-values computed using
A/B and B/A to be approximately equal.
The sum of the number of tests for all ratios is
423,645,558 as shown in Additional file 1: Table S3. The
multiple testing threshold for the ratios using Bonferroni
correction at nominal p-value of 0.05 is 1.18E-10. This
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of magnitude over the genome-wide threshold estimated
by Illig et al. which is 3.63E-12.Proof of principle: sensitivity
The sensitivity of the method was evaluated based on its
ability to identify the top hits in the previously published
Illig et al. genome-wide association study. The overall sensi-
tivity of the method as well as the interrogation specific
breakdown is shown in Table 2. For example, for the BioCyc
pathway scheme the size of the unique gene set generated
for all the metabolites is shown to be 399. The number of
genes that are among the 15 top hits in the Illig et al. study
for this database:interrogation scheme is 8 which results in a
sensitivity measure of 0.53. A metabolite specific breakdown
of each of these schemes and the genes with a p-value cut-
off of 1E-02 is shown in Additional file 1: Table S5.
Overall, combining the results from the four database:
interrogation schemes helped identify 10 of the 15 top
associations (67% sensitivity) published by Illig et al.Novel discovery in the Illig et al dataset
Analysis of the first stage or the “discovery stage” dataset
of 1029 samples from the Illig et al. dataset yielded several
associations with p-values indicative for association, but
that did not meet the significance threshold applied by
Illig et al. Associations with p-value less than 1E-02 were
evaluated in the combined “replication stage” dataset with
1809 samples. Analysis of SNPs in the ALDH1L1 (alde-
hyde dehydrogenase family 1 L1) gene locus lowered the
p-value of association with serine/glycine ratio from
4.83E-09 in the discovery dataset to 5.13E-12 in the com-
bined dataset. This is well below our threshold of 1.18E-
10, but above the threshold to be applied when consider-
ing all associations between SNPs and metabolite ratios.
Furthermore, the original publication did not select this
association for replication because of the threshold set in
the first stage of the analysis. This is an example of the
method pointing to potential true positives in a genome-
wide scan and the association of ALDH1L1 with the trait
is being reported as a novel discovery.Table 2 Performance of the database:interrogation schemes i
Database: interrogation scheme Size of gene set1 Top hits from
BioCyc pathway 399 ACADL, ACADM,
BioCyc reaction 806 ACADM, ACADS,
KEGG pathway 703 ACADL, ACADM,
KEGG reaction 768 ACADL, ACADM,
Pooled set 1246 ACADL, ACADM,
Snapshot of the matches between our method and the association data from the Illig
the unique set of genes generated for all the metabolites for the given database:interr
were present in the gene set for the given database:interrogation scheme. 3Sensitivity
is equal to the ratio of the number of top hits identified by the method over the totalStatistical threshold in the replication study
The analysis of the Illig et al. dataset identified several bio-
logically relevant candidate genes with p-values less than
1E-02. A list of 56 of these genes associated with phospha-
tidylcholines and sphingomyelins were investigated in an
independent study in the GWAS dataset of phospholipids
published by Demirkan et al. The number of matches be-
tween the two datasets was: 56 phosphatidylcholines and 6
sphingomyelins. Demirkan et al. also performed GWAS
for within class molar proportions for these moieties. We
took these into consideration in addition to the GWAS of
absolute concentrations. Therefore, the total number of
metabolites and proportions investigated in the Demirkan
et al. GWAS dataset was 124. A principal component ana-
lysis based on the method proposed by Li et al. [16] was
performed on this set of metabolites resulting in 51 effect-
ively independent variables. As we considered 2413 inde-
pendent SNPs in the candidate loci for these metabolites,
the statistical threshold, applying Bonferroni correction at
a nominal p-value of 0.05, for the replication study was
4.06E-07 (0.05/2413*51).
Novel discoveries in the replication study
Table 3 shows the top hits in the meta-analysis of candi-
date genes identified in the Illig et al. dataset for replica-
tion. The meta-analysis was performed using Stouffer’s Z-
score based method of combining p-values [17]. Since the
SNPs in the loci replicated in the Demirkan et al. dataset
had relatively low r2 values with the SNPs reported in the
Illig et al. dataset, we could not perform a traditional
meta-analysis where strict linkage disequilibrium criteria
are applied. Therefore, we combined the lowest p-value
per gene and sought additional supporting evidence for
potential allelic heterogeneity (see Discussion). As men-
tioned earlier, the p-value threshold for the replication
study is set at 4.06E-07. SNPs in the vicinity of the genes
CBS, GPAM, ADCY8, CNR1, HSD17B12, MBOAT1,
PECR, PLCB1 and TECR pass this threshold.
Discussion
Genome wide association studies with metabolites as
phenotypes have identified several loci that explainn GWAS dataset analysis
Illig et al. study identified by the method2 Sensitivity3
ACSL1, CPS1, FADS1, PHGDH, SCD, SPTLC3 0.53
ACSL1, CPS1, FADS1, SCD, SPTLC3 0.47
ACADS, ACSL1, CPS1, ELOVL2, FADS1, PHGDH, SCD, SPTLC3 0.67
ACADS, ACSL1, CPS1, PHGDH, SCD, SPTLC3 0.53
ACADS, ACSL1, CPS1, ELOVL2, FADS1, PHGDH, SCD, SPTLC3 0.67
et al. 2010 study for each of the database:interrogation scheme. 1corresponds to
ogation scheme. 2corresponds to the top hits in the Illig et al. publication that
is a measure of the actual positives that have been captured by our method and
number of top hits in the Illig et al. publication which is 15.
Table 3 Replication of candidate genes in the Demirkan et al. dataset
Gene Trait SNP from the
Illig et al.
dataset
p-value1 SNP from the
Demirkan
et al. dataset
p-value2 Combined
p-value3
ADCY8 PC ae C40:6 rs11786743 4.03E-05 rs913819 6.73E-04 2.15E-07
CBS* PC ae C40:6 rs2839631 5.67E-06 rs378376 5.17E-04 2.90E-08
CNR1 PC ae C38:2 rs10485168 2.42E-04 rs9359765 4.61E-04 7.54E-07
GPAM* PC ae C34:3 rs2246253 1.25E-04 rs2419603 1.76E-04 1.56E-07
HSD17B12 PC aa C34:4 rs2862999 2.66E-05 rs11037685 6.13E-04 1.35E-07
MBOAT1 PC ae C40:6 rs9465673 1.11E-04 rs694094 4.47E-04 3.53E-07
PECR PC aa C38:0 rs3770536 5.55E-04 rs3770562 9.43E-05 3.79E-07
PLCB1 PC aa C30:0 rs6056188 9.55E-06 rs17363114 1.96E-03 2.06E-07
TECR PC aa C32:0 rs7252966 1.69E-05 rs7254215 2.09E-03 3.57E-07
Top hits from the meta-analysis of candidate genes identified in the Illig et al. study and replicated in the Demirkan et al. dataset. 1,2,3p-value of association of the
SNP with the trait in the Illig et al., Demirkan et al. and combined p-value respectively. *indicates genes for which further evidence was found.
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tabolite panel being tested results in a severe multiple
testing burden that precludes genuine SNP-metabolite
pairs from consideration when they fail to reach the
stringent threshold for statistical significance. Our
method aims to address this problem by selectively test-
ing genes that operate in reactions and pathways rele-
vant to the metabolite. The goal is to reduce the severity
of the multiple testing burden and identify potential true
positives in the list of genome-wide associations. Tav-
erna, a workflow management system was used to gen-
erate the SNP-metabolite pairs. We have deposited the
workflows at a repository called myexperiment.org, mak-
ing it easier for the scientific community to interpret, re-
peat and reproduce the result. The sensitivity of the
method, defined as retrieval of previously identified as-
sociations, is high, as evident from the proof of principle
study carried out on the genome scan published by Illig
et al. Replication studies on some of the promising SNP-
metabolite pairs identified by the method pointed to a
novel and statistically significant association at the
ALDH1L1 locus with serine/glycine ratios. Additional
replication studies of phosphatidylcholines and sphingo-
myelins uncovered significant gene-wise associations
with CBS, GPAM, ADCY8, CNR1, HSD17B12, MBOAT1,
PECR, PLCB1 and TECR.
Databases, interrogation schemes and software tool
The pathway databases have technical and conceptual
differences [11] that mandate interrogation of multiple
databases and integration of the results. Interpretation of
these results requires a close coordination between biol-
ogists and computer scientists. Workflow management
systems in general and Taverna [Additional file 1: S2] in
particular is an example of a software tool that is intui-
tive enough for the biologist, while at the same time of-
fering the flexibility for exploring the algorithmic aspectsfor the computer scientist [18]. In using Taverna as a
software tool and depositing the workflows in the re-
pository myexperiment.org, we have attempted to make
the method and the rationale transparent to users, thus
facilitating its retrieval, reuse and reproduction by other
independent scientists [19].
Sensitivity of the method
As a sensitivity measure of our method, we evaluated its
ability to pick the top hits in the Illig et al. publication
[2]. Some 60% of the top associations were identified
successfully. A similar analysis of GWAS dataset pub-
lished by Suhre et al. [3] yielded a sensitivity of 54% (20
out of 37 hits) (data not shown). However, 4 of the “mis-
ses” in the Suhre et al. dataset were peptide fragments
that do not have an entry in the pathway databases,
which is a prerequisite for our method to work.
We interpret the high sensitivity of our method in three
ways; first it reinforces the rationale that GWAS with
metabolomic phenotypes provides a functional approach
to the study of human genetic variation [1]. In other
words, the known function of the associated gene and the
biochemical characteristics of the affected metabolite sup-
port each other in ways that lends itself to a narrative on
the underlying biological mechanism. Second, while the
pathway databases have a long way to go in achieving a
comprehensive annotation and delineation of biological
processes, they, however, are a good resource of informa-
tion in so far as the top hits in a GWAS with metabolomic
phenotypes are concerned. Only two out of the 15 top hits
in the study by Illig et al. were genes with unknown func-
tions (PLEKHH1, SYNE2), and two others were hitherto
uncharacterized solute transporters (SLC16A9, SLC22A4).
Third, a good sensitivity measure is a validation of our
method and reflects its comprehensive data collection
ability through integration of disparate data sources and
utilization of appropriate interrogation strategies.
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Our analysis of the GWAS dataset of the Illig et al. publi-
cation based on the first step of the “discovery design”
yielded several interesting associations that had not been
reported among the top hits in the publication. We se-
lected a few of the promising associations for replication
in the combined dataset of 1809 subjects. One of the
genes, Aldehyde dehydrogenase family 1 L1 (ALDH1L1)
was found associated with the ratio of serine/glycine with
a p-value of 5.13E-12 in the combined set of 1809 subjects.
ALDH1L1 also known as 10-formyltetrahydrofolate de-
hydrogenase (10-FTHFDH, FDH) catalyzes the NADP+
dependent oxidation of 10-formyltetrahydrofolate to CO2
and tetrahydrofolate (THF) [20] as shown in Figure 4. It
plays an important role in folate metabolism [21-25].
Among other functions, ALDH1L1 has been known to de-
plete cellular 10-formyltetrahydrofolate pool resulting in a
loss of de novo purine biosynthesis [23], maintain cellular
folate concentrations by regulating the availability of THF
[22], but most importantly, it has been shown to compete
with the enzyme serine hydroxymethyl transferase
(SHMT) for the polyglutamyltetrahydrofolates [25]. The
latter enzyme catalyzes the conversion of serine to glycine
as shown in Figure 4. It has also been shown that glycine
to serine inter-conversion by SHMT accounts for approxi-
mately 41% of whole body glycine flux inclusive of both
mitochondrial and cytoplasmic processes [26].
To further investigate the potential of our approach to
uncover novel genetic associations, we extended the ana-
lysis to an additional independent GWAS dataset [4].
Candidate genes identified in the Illig et al. dataset in as-
sociation with phosphatidylcholines and sphingomyelins
were considered for replication in the dataset provided
by Demirkan et al. [4]. We discuss here two novel find-
ings for which additional evidence was obtained.ALDH1L1
Glycine
10
5,10-M
5,10-M
5,10
THF
Serine
SHMT
Figure 4 Role of ALDH1L1 in the cytosolic one-carbon pool metabolis
cytosol is depicted. ALDH1L1: Aldehyde Dehydrogenase 1 Family, MemberSNPs near glycerol-3 phosphate acyltransferase
(GPAM) are associated with PC ae C34:3 moieties in the
Illig et al. and Demirkan et al. datasets with p-values of
1.25E-04 and 1.75E-04, respectively, with a meta-analysis
p-value of 1.56E-07. GPAM encodes a mitochondrial
protein that esterifies the acyl group from acyl-coA to
the sn-1 position of glycerol-3-phosphate. It is a rate-
limiting enzyme that catalyzes the initial step in the bio-
synthesis of triacylglycerols and phospholipids [27]. A
recent study showed that in breast cancer, GPAM ex-
pression is strongly correlated with survival rates,
clinico-pathological features as well as metabolomic and
lipidomic profiles [28]. Interestingly, the study identified
the metabolite PC C34:3 as the most significantly altered
metabolite with respect to GPAM expression in breast
cancer patients. This suggests that, for this particular ex-
ample, genetic control is primarily at the level of gene
expression, with secondary effects on enzyme levels and
metabolic conversion rates. The example also highlights
the potential influence of genetic variation of metabolic
pathways on disease.
A large number of genes identified by our method in
the context of phospholipids participate in fatty acid me-
tabolism and are therefore likely to affect the levels of
groups of phosphatidylcholines and sphingomyelins. For
example, GPAM esterifies the acyl group from acyl-ACP
to the sn-1 position of glycerol-3-phosphate, and is
therefore relevant to both acyl-acyl and acyl-alkyl moi-
eties. The lowest p-value of association, at this locus,
with a phosphatidylcholine moiety in the Illig et al. study
is with PC ae C36:3, while in the Demirkan et al. study it
is PC aa C36:3. Since both associations make biological
sense, future work should incorporate joint modelling of
suitable phospholipid moieties to help identify loci that
are biologically relevant but fail to reach the statistical-FormylTHF
ethenylTHF
ethyleneTHF
-MethylTHF
Methionine
Purines
Thymidylate
m. A simplified schematic of the one-carbon pool metabolism in the
L1; THF: tetrahydrofolate; SHMT: Serine hydrxymethyltransferase.
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best case associations for phosphatidylcholines in
Additional file 1: Table S6.
SNPs near Cystathionine beta-synthase (CBS) are asso-
ciated with PC ae C40:6 moieties in the Illig et al. and
Demirkan et al. datasets with p-values of 5.67E-06 and
5.17E-04, respectively, with a meta-analysis p-value of
2.9E-08. Mutations in CBS cause hyperhomocysteinemia
[29], which is marked by elevated levels of homocyst-
eine. Several studies have associated altered phosphat-
idylcholine biosynthesis with hyperhomocysteinemia/
CBS deficiency [30-33]. In one of the studies [30], phos-
phatidylcholine levels and the activity of the enzyme
lecithin-cholesterol acyltransferase (LCAT) were signifi-
cantly lower in CBS deficient mice than in wild type
mice. While there is considerable literature evidence for
the role of CBS in phosphatidylcholine metabolism, the
stringent p-value threshold obscures this association in
the list of GWAS results.
The low r2 values for significant SNPs in GPAM, CBS
and other loci between the Illig et al. and Demirkan
et al. datasets could be explained by allelic heterogeneity.
The latter is a phenomenon where multiple alleles from
one gene influence a trait. However, in some cases it
may be that the two apparently independent SNPs are
tagging a third SNP [34]. This may be the case for the
two SNPs (rs2839631, rs378376) near CBS which have
an r2 of 0.067 and are associated with C40:6 phosphati-
dylcholines in both the datasets. However, both SNPs
are in LD with cis-eQTLs in the region (for example,
rs719037, r2 ~ 0.4). This is suggestive of the SNPs exert-
ing their effect through the expression levels of the CBS
enzyme, as was suggested for GPAM. Apparent allelic
heterogeneity may preclude identification in a standard
meta-analysis, but would justify further investigation of
independent or dependent signals at loci showing this
phenomenon.
Challenges and future direction
In general, our effort was directed at exploring the utility
of machine-enabled interrogation of metabolic pathway
databases in prioritizing SNP-metabolite associations in
a GWAS dataset. While the method’s sensitivity and
ability to make novel discovery are encouraging, consid-
erable progress needs to be made in metabolite disam-
biguation to achieve a relevant and comprehensive gene
set for a given metabolite. This problem is particularly
acute for phospholipids like phosphatidylcholines and
sphingomyelins and various forms of the fatty acid trans-
porters of L-carnitine. For example, the metabolomics
technology used in the Illig et al. study differentiated
more than 90 forms of phosphatidylcholines based on
alkyl or acyl bonds and single or double bonds on the
side chains. However, the pathway databases do not yetcontain information for the complex structures. This
forces users to analyze these metabolites at a higher ag-
gregation level. Another issue that requires attention is
the bias introduced in selecting genes for inclusion in
the gene set. We have formulated simple rules for inter-
rogation [Additional file 1: S1] that facilitates unbiased
generation of gene sets for any given metabolite.
Another challenge arises due to the high correlation be-
tween metabolites, particularly the phospholipids like
phosphatidylcholines and sphingomyelins. These moieties
are associated with loci relevant to fatty acid metabolism.
While the variation at these loci effects the levels of fatty
acids and thereby the phospholipid pool, to a large extent,
these loci are not specific for any particular phospholipid
moiety. As a result, several loci exhibit a pleiotropic effect
for biologically related metabolic phenotypes in general
and phospholipids in particular [Shown in Additional file
1: Table S7] We have demonstrated that background
knowledge and evidence-based approach is ideally suited
to identify such candidate genes, however future work
should focus on statistical methodologies with sufficient
power to detect such pleiotropic loci in GWAS of inter-
mediate phenotypes. In summary, future work includes
integration of more pathway databases, metabolite disam-
biguation, consideration of allelic heterogeneity and
multivariate statistical techniques that take into ac-
count the high degree of correlation between the
metabolites.
Conclusions
A measurement of metabolites as intermediate pheno-
types is a potentially powerful approach to uncover the
influence of genetic variation on disease susceptibility
and progression. However, we still face many hurdles in
the interpretation of GWAS data. In this study, we in-
vestigated the utility of background knowledge present
in pathway databases in extending our understanding of
the genetic basis of metabolic variation. We developed a
bioinformatics method that prioritizes SNP-metabolite
associations in a GWAS based on metabolic pathway in-
formation present in the KEGG and BioCyc databases.
The validity of the method is demonstrated by re-
analysing published GWAS datasets and identifying pre-
viously known associations. We report a new locus of
human metabolic individuality, ALDH1L1 (Aldehyde de-
hydrogenase family 1 L1) associated with serine/glycine
ratios. Replication studies in an independent GWAS of
phospholipids identified GPAM (Glycerol-3 phosphate
acyltransferase) and CBS (Cystathionine beta-synthase)
as novel loci, and this was further supported by add-
itional literature evidence. The utility of a workflow
management system in facilitating novel biological dis-
coveries and as a tool for efficient sharing of computa-
tional protocols is demonstrated.
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GWAS data set for proof of principle studies
The GWAS dataset published by Illig et al. 2010 [2] was
used to evaluate the validity of the method. Illig et al.
employed a two-stage discovery design in the KORA F4
population cohort with 1029 male and female individuals
in the first stage and 780 individuals in the second stage.
Loci with p-value of association <10-7 for metabolite
concentrations and p-value < 10-9 for concentration ratios
were taken up for the second stage independent testing in
780 individuals. The joint p-values of association for all
the 1809 individuals were then computed and 15 loci were
reported whose strength of association increased after the
second stage of the discovery process. The authors note
that “although this approach is less well powered than a
full genome-wide joint analysis, it reflects the historical
way in which [they] selected SNPs for follow-up”. This
means that if we can identify potential true positives using
the 1029 samples, we can validate them in the full dataset,
since this has not been done in the Illig et al. study for all
hits with p-value > 10-7 for metabolite concentrations and
p-value > 10-9 for concentration ratios. Therefore, the
GWAS dataset based on 1029 samples was analyzed for
our proof of principle studies. Additionally, to evaluate
novel associations identified by the method in the discov-
ery stage dataset, the strength of the signal was assessed in
the combined GWAS dataset for 1809 subjects.
GWAS dataset for follow-up studies
Candidate loci identified in the Illig et al. dataset by our
method were taken up for follow-up studies in the dataset
published by Demirkan et al. The latter conducted a meta-
analysis of GWAS on plasma levels of ceramides, phos-
phatidylcholines, lysophosphatidylcholines, sphingomye-
lins, phosphatidylethanolamines and plasmalogens in five
European populations: the Erasmus Rucphen Family
(ERF) study, conducted in the Netherlands, (2) the
MICROS study from the Tyrol region in Italy, (3) the
Northern Swedish Population Health Survey (NSPHS) in
Norrbotten, Sweden, (4) the Orkney Complex Disease
Study (ORCADES) in Scotland, and (5) the CROAS
(CROATIA_Vis) study conducted on Vis Island, Croatia.
Broadly, the metabolite overlap between the Illig et al. data-
set and Demirkan A et al. dataset was confined to the class
of phosphatidylcholines, lysophosphatidylcholines and
sphingomyelins. More specifically, the overlap represented
62 phospholipid moieties. Also, 56 candidate genes were
identified for follow up in the Illig et al. dataset. We choose
to focus on SNPs in the flanking 50 kb region of these genes
for the follow-up study in the Demirkan A et al. dataset.
Metabolites considered for the generation of gene sets
Gene sets are defined as entities that participate in path-
ways and reactions relevant to the metabolite and hencehold the potential to influence its levels. The goal was to
generate gene sets for the compounds that were mea-
sured in the Illig et al. 2010 publication: 14 amino acids
(Arginine, Glutamine, Glycine, Histidine, Methionine,
Ornithine, Phenylalanine, Proline, Serine, Threonine,
Tryptophan, Tyrosine, Valine, and Leucine), 41 Carni-
tines, 92 Phosphatidylcholines and 15 Sphingomyelins.
In addition to the metabolites mentioned above, Illig
et al. also measured Hexose. We did not consider this
metabolite for investigation because pathway informa-
tion surrounding hexose is lacking. While metabolites
like glucose and fructose could have been considered as
proxies, we did not pursue this because of the enormous
size of the resulting gene set, combined with a lack of
confidence in the relevance of many of these genes to
the metabolite measured by the metabolomics platform.
Pathway databases and interrogation schemes
The metabolic pathway databases KEGG (release 63)
[12] and BioCyc (version 16) [13] were accessed for re-
trieving background knowledge surrounding metabolites.
Two interrogation schemes were employed: pathway
scheme and reaction scheme (Figure 1). In a pathway
scheme, for a given metabolite, all the pathways that it
participates in are determined followed by the retrieval
of all the genes that participate in these pathways
(Figure 1A). In a reaction scheme, given a metabolite, all
the reactions that it is part of and the compounds that
participate in these reactions are determined. The com-
pounds obtained at this point are subjected to the same
strategy as in the previous step in that all the reactions
that these compounds participate in are determined.
This can be visualized as expanding by a radius of 2
steps in the reaction space of every metabolite. Finally,
the enzymes that drive all these reactions are determined
(Figure 1B). As an intermediate step certain compounds
were filtered out in order to avoid non-specific connec-
tions. The details about the filtration step and the com-
pounds that were filtered are provided in the Additional
file 1: S4. In all there are four schemes: kegg:pathway,
kegg:reaction, biocyc:pathway, and biocyc:reaction. The
set of non-redundant genes combined from all the
schemes then forms the gene set for any given metabolite.
Software used to generate gene and SNP sets
Taverna version 2.4 [14], a workflow management sys-
tem was used to generate metabolite specific gene sets
as well as for the generation of SNPs present in the
50 kb flanking region of each gene. Taverna allows users
access to remote data resources like KEGG, BioCyc,
Ensembl, NCBI etc. and data management systems like
Biomart through implementation of web services. Each
component in a workflow is responsible for a particular
function and many such components need to be chained
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a certain task. The pipeline depicted in Figure 1 is im-
plemented in a Taverna workflow through appropriate
linking of remote web services and local scripts. Web
services are software systems that facilitate machine to
machine interaction over a network. Taverna allows the
inclusion of different kinds of web services like Web Ser-
vices Description Language (WSDL) and REpresenta-
tional State Transfer (REST). The services provided by
the KEGG database were implemented using the REST
services made available in the Taverna workbench. The
BioCyc database was accessed through the REST inter-
face using the BioVelo language. The latter is a query
language designed to let the users write precise queries
against the pathway/genome databases, available at Bio-
Cyc, to retrieve pathways, reactions, compounds, genes
etc. All the workflows were designed following best
practices for workflow design [35].
Workflow accessibility
To facilitate retrieval and reproducibility, the workflows
have been deposited in a repository at http://www.myex-
periment.org/packs/319.html. While the focus of this
paper was on a specific set of metabolites; using appro-
priate identifiers from the KEGG or BioCyc database
users will be able to generate gene sets for other metab-
olites. To generate a gene set for any metabolite using
the KEGG or BioCyc database, users have to input the
metabolite identifier for that database and the output is
a text file containing the entrez gene identifiers. For ex-
ample, to generate a gene set for the metabolite Argin-
ine, for either the pathway or reaction scheme using the
KEGG database, users input the KEGG identifier for Ar-
ginine: C00062. Similarly, to obtain a gene set using the
BioCyc database, the input for the same metabolite is
“L-arginine”. The workflows may also be repurposed to
suit other objectives, for example, to filter out non-
specific connections, we remove hub metabolites like
ATP, NADP and other entities like co-enzymes; however,
users may change the filtration criteria if they find it too
stringent for their objectives. A detailed tutorial on how
to access and run these workflows is provided in the
Additional file 1: S2.Additional file
Additional file 1: S1. Rules to generate Metabolite-Gene sets. S2. Taverna
workflow management system. Figure S1. Snapshot of the Taverna
workbench which consists of three panels as pointed to in the figure.
Table S3. SNP set generated for ratios of metabolites. S4. Compounds
filtered for the Kegg:Reaction Scheme. Table S5. Metabolite specific
break-up of the performance of database:interrogation schemes.
Table S6. Best case associations of loci with phosphatidylcholines in
the Illig et al and Demirkan et al datasets. Table S7. Pleiotropic effect
for phosphatidylcholines at select loci.Competing interests
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